Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000691418 | SCV000819196 | uncertain significance | Spastic ataxia 2 | 2024-01-22 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 1030 of the KIF1C protein (p.Arg1030Cys). This variant is present in population databases (rs62072492, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with KIF1C-related conditions. ClinVar contains an entry for this variant (Variation ID: 570542). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ce |
RCV000996460 | SCV001151171 | uncertain significance | not provided | 2018-05-01 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001849055 | SCV002105329 | uncertain significance | Hereditary spastic paraplegia | 2017-03-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002544910 | SCV003536356 | uncertain significance | Inborn genetic diseases | 2021-10-12 | criteria provided, single submitter | clinical testing | The c.3088C>T (p.R1030C) alteration is located in exon 23 (coding exon 21) of the KIF1C gene. This alteration results from a C to T substitution at nucleotide position 3088, causing the arginine (R) at amino acid position 1030 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |